Authors: van der Schaaf, R. J., Claessen, B. E., Hoebers, L. P., Verouden, N. J., Koolen, J. J., Suttorp, M. J., BARBATO, EMANUELE, Bax, M., Strauss, B. H., Olivecrona, G. K., Tuseth, V., Glogar, D. j., Råmunddal, T., Tijssen, J. G., Piek, J. J., Henriques, J. P. S.
Contributors: van der Schaaf, R. J., Claessen, B. E., Hoebers, L. P., Verouden, N. J., Koolen, J. J., Suttorp, M. J., Barbato, Emanuele, Bax, M., Strauss, B. H., Olivecrona, G. K., Tuseth, V., Glogar, D. j., Råmunddal, T., Tijssen, J. G., Piek, J. J., Henriques, J. P. S.
Subject Terms: acetylsalicylic acid, antilipemic agent, beta adrenergic receptor blocking agent, clopidogrel, dipeptidyl carboxypeptidase inhibitor, everolimu, prasugrel, cardiovascular agent, drug derivative, rapamycin, acute disease, artery occlusion, article, chronic total occlusion, clinical research, clinical trial, controlled clinical trial, controlled study, follow up, heart left ventricle enddiastolic volume, heart left ventricle function, heart ventricle remodeling, human, major clinical study, methodology, multicenter study, nuclear magnetic resonance imaging, percutaneous coronary intervention, randomized controlled trial, recanalization
Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000282599400001; volume:11; journal:TRIALS; https://hdl.handle.net/11573/1660357; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-77956692768
